KATERINA BAKELA, Greece

UNIVERSITY OF CRETE BIOLOGY
Dr Bakela Katerina is 35 years old and has completed her PhD at the age of 30 years (2015) from Biology Department, University of Crete and currently is employed as a postdoctoral researcher in Immunobiology Lab, University of Crete. She is the recipient of 2 postdoctoral fellowships, from State Scholarships Foundation (IKY)-SIEMENS and EU Partnership Agreement (PA) 2014-2020 for young researchers. Dr Bakela has supervised over 10 postgraduate and 25 undergraduate thesis and has published so far 6 papers in reputed journals. Furthermore, she has presented her research in more than 20 global, European and Greek meetings and conferences.

Presenter of 1 Presentation

 Conference Calendar

RESCUE OF AUTOIMMUNE HEPATITIS BY SOLUBLE MHC-II MOLECULES IN AN IN VITRO AND IN VIVO MURINE EXPERMENTAL MODEL

Session Name
PS06 - LIVER AND AUTOIMMUNITY
Session Type
PARALLEL SESSIONS
Date
29.05.2021, Saturday
Session Time
10:00 - 12:00
Room
HALL F
Lecture Time
10:10 - 10:20
Presenter
Session Icon
Pre Recorded

Abstract

Background and Aims

Soluble MHC class II (sMHC-II) molecules are present in all body fluids of healthy individuals and have been described as molecules maintaining tolerance through the suppression of autoreactive T lymphocytes. Since sMHC-II were successfully shown to alleviate Systemic Lupus Erythematosus symptoms in an experimental mouse model, in the present study it was attempted to administer sMHC-II to a model of experimental, concanavalin A (conA) induced autoimmune hepatitis (AIH).

Methods

This model highly represents the chronic liver inflammation in AIH and is examined by imbalanced interleukin secretion in serum. Experimental tests were performed both in vitro and in vivo.

Results

Following the mitogenic stimulation of spleen cells with conA in vitro, syngeneic sMHC-II, isolated from healthy mouse serum and identified by ELISA and SDS-PAGE, lead to a significant reduction of activated spleen cells, as assessed by tritiated thymidine incorporation assays. The in vivo experimental model was induced by conA injections in male BALB/c mice. The administration of syngeneic sMHC-II in conA-treated mice showed a significant reduction in the levels of IL-2, IL-4 and IL-10, as well as a decrease in the number of the activated splenic T-lymphocytes, as tested by ELISA and immunofluorescence experiments, respectively. In addition, a slower progression in the phenotypical characteristics of the disease was observed, while liver scans showed milder tissue damage in mice who had received sMHCII.

Conclusions

Therefore, the results presented in this study confirm the suppressive ability of the sMHC-II molecules in the model of experimental AIH, possibly highlighting new therapeutic approaches for autoimmune diseases.

Hide